OWA
CGTX icon

Opal Wealth Advisors’s Cognition Therapeutics CGTX Stock Holding History

Opal Wealth Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$830 – 360
2024
Q2 		$830 Buy
+500
New +$997 ﹤0.01% 1099

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Opal Wealth Advisors's CGTX Position: Q3 2024 in Review

Opal Wealth Advisors sold out of Cognition Therapeutics (CGTX) in Q3 2024, closing a stake of 500 shares — an estimated $830 sold.

Opal Wealth Advisors first reported a position in CGTX in Q2 2024 and held it in 1 quarter. The position peaked at $830 in Q2 2024. 40 funds tracked by Wall St. Rank hold CGTX as of Q3 2024.

  • Opal Wealth Advisors reported no remaining Cognition Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Opal Wealth Advisors sold 500 Cognition Therapeutics shares in Q3 2024, an estimated $830.
  • Opal Wealth Advisors first reported a position in Cognition Therapeutics in Q2 2024 and held it in 1 quarter.
  • Opal Wealth Advisors's Cognition Therapeutics position peaked at $830 in Q2 2024.
  • 40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2024.

Based on Opal Wealth Advisors's 13F filing for Q3 2024, filed 15 Oct 2024.